Dean Tuck – Managing Director – Dreadnought Resources (ASX:DRE) is a highly active West Australian mineral explorer focused on finding the metals needed now and in the future.
Copyright 2023 – Finance News Network
Source: Finance News Network
28 Sep 2022 - Meeka Metals Limited (ASX:MEK) Managing Director and CEO Tim Davidson discusses recent gold and rare earths results and the outlook for the next year.
Read More29 Sep 2023 - Shanthar Pathmanathan, CEO and founder of Chariot Corporation (ASX:CC9) discusses US lithium mining opportunities and expansion plans.
Read More18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
Read More24 Oct 2019 - BOTTY Limited Founder & CEO, Cary Gee, talks about his Conversational Commerce solution for merchants and how it leverages existing social messaging platforms to create an integrated customer engagement, analytics, payment and delivery solution.
Read More23 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
Read More05 Feb 2020 - Centuria Industrial REIT (ASX:CIP) Fund Manager, Jesse Curtis talks 1H20 results, portfolio metrics and trends.
Read More11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
Read More27 Sep 2023 - Geoff Selig, Executive Chairman of IVE Group Limited (ASX:IGL), discusses FY23 results and the acquisition of Ovato.
Read More30 Sep 2019 - Symposium, Managing Director, Kerry Stevenson talks about the importance of gold in a diversified portfolio, its successful performance over the past 12 months and all that’s on offer at this year’s event, 24-26 October, Sydney Sofitel Wentworth.
Read More11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
Read More
